Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - deltamethrin - pour-on solution - 10 milligram(s)/millilitre - deltamethrin - cattle, sheep - ectoparasiticide

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin - solution for infusion - 400 mg - active: moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - avelox tablets and solution for infusion is indicated for the treatment of the following bacterial infections caused by susceptible strains: · complicated intra-abdominal infections including polymicrobial infections such as abscesses

United Kingdom - English - VMD (Veterinary Medicines Directorate)

virbac - eprinomectin - pour-on solution - endectocide - cattle

United Kingdom - English - VMD (Veterinary Medicines Directorate)

virbac - deltamethrin - pour-on solution - ectoparasiticide - cattle, sheep

Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - eprinomectin - pour-on solution - 5 mg/ml - eprinomectin - bovine - endectoparasiticides

Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - deltamethrin - cutaneous solution - 10 mg/ml - deltamethrin - bovine, ovine - ectoparasiticide

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - gatifloxacin 2 mg/ml;   - solution for infusion - 2 mg/ml - active: gatifloxacin 2 mg/ml   excipient: glucose hydrochloric acid sodium hydroxide water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 400 mg (equivalent: moxifloxacin hydrochloride, qty 436.8 mg) - tablet, film coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; hypromellose; ferric oxide; croscarmellose sodium; lactose monohydrate; magnesium stearate; macrogol 400 - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

India - English - Central Drugs Standard Control Organization

medley - gatifloxacin,ambroxol - tab - 400,75(sr);mg - 10

Bangladesh - English - DGDA (Directorate General of Drug Administration)

beacon pharmaceuticals plc - baclofen - tablet - 5 mg